Public register entity · Japan
日本新薬株式会社
E00931.JP
- Basis
- consolidated
- Source
- FSA EDINET ↗
Financial data filed with a public register. Not a listed company and not a tradable security — this page carries no price and no forecast.
Public register entity · Japan
E00931.JP
Financial data filed with a public register. Not a listed company and not a tradable security — this page carries no price and no forecast.
As first reported — the figures as originally filed, not later restatements.
Latest filing: FY2026 · 2026-03-31Filed 2026-06-23
| Metric | Value |
|---|---|
| Revenue | 170.8B |
| Net income | 29.7B |
| Total assets | 346.4B |
| Total equity | 291.6B |
| Cash | 76.6B |
| EPS (diluted) | 441.00 |
| Net margin | 17.4% |
| Return on equity | 10.2% |
| Return on assets | 8.6% |
Free, no sign-up — built from official regulator filings.
出典：EDINET閲覧（提出）サイト（https://disclosure2.edinet-fsa.go.jp/）、公共データ利用規約（第1.0版）PDL1.0（https://disclosure2dl.edinet-fsa.go.jp/guide/static/disclosure/WZEK0030.html） — Source: Financial Services Agency (Japan), EDINET, under Public Data License 1.0